Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Declines By 36.1%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 167,500 shares, a decline of 36.1% from the January 31st total of 262,100 shares. Approximately 6.1% of the company’s stock are sold short. Based on an average trading volume of 437,800 shares, the days-to-cover ratio is currently 0.4 days.

Theriva Biologics Price Performance

Shares of Theriva Biologics stock opened at $1.44 on Friday. Theriva Biologics has a 1-year low of $1.14 and a 1-year high of $17.11. The stock has a market cap of $4.00 million, a price-to-earnings ratio of -0.04 and a beta of 1.22.

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP acquired a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.17% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Maxim Group decreased their target price on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.